

# 创新引领 全球运营 挖掘增长潜力

直观复星深耕上海领跑手术机器人赛道  
聚焦创新药，复星医药全资收购复星凯特  
翌耀科技全球总部启用，打造“智造”高地  
复星旅文资产优化稳步推进  
舍得酒旅融合再启新篇章



" " 9 19 36




" " 2023 6 "

" Ion 3 7

5 23 "

6 7



" 1992 "

CAR-T 700 --- B

2017

Glenn Vavoso

52 3000

2023 15 220

2023 370

48

60

100%

2024 9 13 600196.SH 02196.HK

Kite Pharma CAR-T

CAR-T

Kite Pharma

Kite Pharma

50%

100%

Kite Pharma

2017 Kite Pharma

CAR-T

90 Kite Pharma 1,000

Pharma

2,500

Kite

7% -

13%

Kite Pharma



“ ” 2024 “ ”  
9 10 “ ”  
2023 “ ”  
“ ”

“ ”

	2018	2019	FFT
	FFT Produktionssysteme		
GmbH & Co.KG		50	
	3000	—	
			2024
			39.9
			7.5
FFT	Tristan Pfurr	2024	
FFT	50		
1974		FFT	



# INTERVIEW

12 2024

978.4  
34.7 7.2  
721.7

74%

" "

8 29 2024

CEO

CEO 4

"

"

12

"

" "

" "

A B  
C

" " " "

D

10%

10% 50

" "

" "

" " Club Med

85%







|

|

2024 9 9 -  
" Sisram" " "  
" "  
" DAXXIFY®  
A  
DaxibotulinumtoxinA- lanm  
RT002

DaxibotulinumtoxinA-  
lanm  
20  
PXT  
1

20 - 25  
72  
2 - 8  
®



9 20 22

19

" "

" "

" "

" "

2025

30

" "



9 13  
Tethys Oil AB " 13.02 "  
" "  
" + "

58 3&4 49 56  
2023  
2P 2170 2024  
7860  
1180 6090  
58.7 18.94  
13.02





